Minimally Invasive Treatment Of Lung Cancer Market Report 2026

Minimally Invasive Treatment Of Lung Cancer Market Overview

• Minimally Invasive Treatment Of Lung Cancer market size has reached to $3.35 billion in 2025 • Expected to grow to $5.21 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Increasing Prevalence Of Lung Cancer Driving The Market Growth Due To Rising Global Incidence And Demand For Advanced Treatment Options • Market Trend: Emerging Advances Driving Innovation In Minimally Invasive Lung Cancer Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Minimally Invasive Treatment Of Lung Cancer Market?

Minimally invasive lung cancer treatment involves using small incisions and advanced techniques, such as video-assisted or robotic surgery, to target or remove lung tumors while causing minimal damage to surrounding tissues. This approach aims to speed recovery, reduce complications, and enhance patient outcomes compared to traditional open surgery. The main types of minimally invasive treatment for lung cancer are lung tumor ablation and lung tumor embolization. Lung tumor ablation is a procedure that destroys lung cancer cells by applying extreme heat or cold directly to the tumor using imaging-guided probes. This treatment affects patients across various stages, such as stages I, II, III, and IV, and age groups include under 30 years, 31–45 years, and 46–60 years. and treatments are used by several end-users, including hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research institutions.

What Is The Minimally Invasive Treatment Of Lung Cancer Market Growth Forecast?

The minimally invasive treatment of lung cancer market size is expected to see strong growth in the next few years. It will grow to $5.21 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing investments in precision cancer care, rising adoption of robotic and AI-assisted oncology treatments, expansion of early-stage lung cancer detection programs, growing demand for outpatient cancer procedures, increasing focus on personalized treatment pathways. Major trends in the forecast period include increasing adoption of image-guided tumor ablation techniques, rising use of minimally invasive embolization procedures, growing integration of robotic assistance in oncology care, expansion of precision oncology treatment platforms, enhanced focus on reduced treatment-related complications.

Global Minimally Invasive Treatment Of Lung Cancer Market Segmentation

1) By Type: Lung Tumor Ablation, Lung Tumor Embolization 2) By Stage: Stage I, Stage II, Stage III, Stage IV 3) By Age Group: Under 30 Years, 31 To 45 Years, 46 To 60 Years 4) By End-User: Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Research Institutions Subsegments: 1) By Lung Tumor Ablation: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Laser Ablation 2) By Lung Tumor Embolization: Bronchial Artery Embolization, Pulmonary Artery Embolization, Chemoembolization, Radioembolization

What Is The Driver Of The Minimally Invasive Treatment Of Lung Cancer Market?

The increasing prevalence of lung cancer is expected to propel the growth of the minimally invasive treatment of lung cancer market going forward. Lung cancer is a type of cancer that originates in the lungs and is characterized by uncontrolled cell growth. Lung cancer is rising largely due to an increase in tobacco smoking, leading to an increased likelihood of uncontrolled cell growth and tumor formation. Minimally invasive treatment helps lung cancer patients by targeting and removing or destroying tumors through small incisions or imaging-guided probes, which reduces recovery time, minimizes damage to healthy lung tissue, lowers the risk of complications, and allows patients to resume normal activities sooner. For instance, in January 2023, According to a report published by the American Cancer Society, a U.S.-based non-profit organization, in 2023, approximately 238,340 individuals, comprising 117,550 men and 120,790 women, are expected to be diagnosed with lung cancer, with an estimated 127,070 deaths resulting from the disease. Therefore, the increasing prevalence of lung cancer is driving the growth of the minimally invasive treatment of lung cancer industry.

Key Players In The Global Minimally Invasive Treatment Of Lung Cancer Market

Major companies operating in the minimally invasive treatment of lung cancer market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Intuitive Surgical Inc., Accuray Incorporated, Richard Wolf GmbH, AngioDynamics Inc., CMR Surgical Ltd., Guangzhou Geyi Medical Instrument Co. Ltd., Quantum Surgical SA, Scanlan International Inc., RZ Medizintechnik GmbH & Co. KG, August Reuchlen GmbH, SBH Surgical GmbH & Co. KG, Geister Medizintechnik GmbH, Cook Medical Incorporated, Terumo Corporation, Merit Medical Systems Inc., Sirtex Medical Limited

Global Minimally Invasive Treatment Of Lung Cancer Market Trends and Insights

Major companies operating in the minimally invasive treatment of lung cancer market are focusing on developing innovative solutions, such as microwave ablation systems and navigation-assisted biopsy platforms, to meet the rising demand for lung-sparing therapies, faster diagnosis, shorter hospital stays and treatment options for patients unfit for open surgery. Microwave ablation (MWA) devices deliver high-frequency electromagnetic energy through a probe to rapidly heat and coagulate tumour tissue, producing predictable spherical ablation zones with faster treatment times and less heat-sink effect than radiofrequency ablation. For instance, in January 2025, Creo Medical Group plc, a UK-based medical device company focused on minimally invasive surgical endoscopy, introduced the MicroBlate Flex soft-tissue microwave ablation system and moved it into clinical study for lung lesions. MicroBlate Flex is composed of a microwave generator and flexible ablation applicator designed for use across multiple soft-tissue indications. It functions by emitting high-frequency microwave energy at the applicator tip to create controlled thermal zones that destroy tumour cells. The system’s unique features include a high-frequency power profile for efficient energy deposition, a flexible delivery design intended to reach difficult anatomies, and compatibility with endoscopic or percutaneous approaches enabling applications in small pulmonary nodules, metastatic lung lesions and patients who cannot tolerate lobectomy. Clinically, this translates into shorter procedure times, reduced need for general anaesthesia, potential outpatient workflows, and an expanded treatment option set when compared with open surgery or stereotactic radiotherapy.

What Are Latest Mergers And Acquisitions In The Minimally Invasive Treatment Of Lung Cancer Market?

In February 2025, the Toulouse University Hospital, a France-based medical institution, acquired Epione from Quantum Surgical for an undisclosed amount. With this acquisition, the Toulouse University Hospital aims to enhance its capacity for minimally invasive, robot-assisted treatment of abdominal and lung tumors, enabling physicians to perform highly precise procedures, improving patient outcomes, reducing recovery times, and expanding access to advanced oncological care in the Occitanie region. Quantum Surgical is a France-based medical technology company that offers minimally invasive management for small and hard-to-reach lung tumors.

Regional Outlook

North America was the largest region in the minimally invasive treatment of lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Minimally Invasive Treatment Of Lung Cancer Market?

The minimally invasive treatment of lung cancer market consists of revenues earned by entities by providing services such as diagnostic imaging, bronchoscopic procedures, chemotherapy delivery, targeted therapy administration and postoperative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimally invasive treatment of lung cancer market also includes of sales of implants, catheters, endoscopes, navigation systems and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Minimally Invasive Treatment Of Lung Cancer Market Report 2026?

The minimally invasive treatment of lung cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the minimally invasive treatment of lung cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.